Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genflow Biosciences Plc ( (GB:GENF) ) just unveiled an announcement.
Genflow Biosciences Plc, a longevity-focused gene therapy developer based in the UK with Belgian R&D operations, is advancing its lead asset GF-1002, which targets age-related decline via a centenarian SIRT6 variant and is under evaluation in canine sarcopenia and longevity studies, alongside a planned clinical programme in MASH. The company has received the first €336,467 tranche of a €4 million non-dilutive grant from Belgium’s Wallonia Region, providing three-year funding aligned with its GF-1002 MASH roadmap and strengthening its financial capacity to pursue key development milestones and sustain progress on its lead programme.
The initial grant disbursement, which will be used for eligible project activities, is the first of several milestone-based instalments expected over the programme’s duration. This regional support underpins Genflow’s positioning in the competitive longevity and metabolic liver disease fields by offering non-dilutive capital, thereby limiting shareholder dilution while potentially accelerating the gene therapy’s path through development and enhancing visibility among investors and partners.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.
Spark’s Take on GB:GENF Stock
According to Spark, TipRanks’ AI Analyst, GB:GENF is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, continued cash burn) and a weakened balance sheet with negative equity. Technicals are moderately supportive given the price trend above key moving averages, but valuation remains pressured due to losses and no dividend support.
To see Spark’s full report on GB:GENF stock, click here.
More about Genflow Biosciences Plc
Genflow Biosciences Plc is a UK-headquartered biotechnology company with R&D facilities in Belgium that focuses on longevity-focused gene therapies. Its lead candidate, GF-1002, delivers a proprietary centenarian variant of the SIRT6 gene and is being evaluated in an ageing-dog study, with additional plans to investigate its potential in treating MASH, a prevalent chronic liver disease lacking effective therapies.
Average Trading Volume: 2,372,272
Technical Sentiment Signal: Buy
Current Market Cap: £9.87M
For detailed information about GENF stock, go to TipRanks’ Stock Analysis page.